Side effect. by My Tra Thi Nguyen (22120541)

“…UAS7 average scores decreased from a baseline mean of 28.9 to 2.9, indicating substantial reduction in disease activity. …”

Table 1_Electroacupuncture improves scopolamine hydrobromide induced dry eye in mice via inhibiting ocular surface inflammation and regulating the HMGB1-related signaling pathways.... by Xia Wu (203682)

“…The levels of HMGB1, RAGE, TLR2, TLR4, and IL-6 were significantly decreased while IL-10 level was significantly increased after EA treatment, indicating that EA may improve dry eye surface inflammation by inhibiting HMGB1-related signaling pathways.…”

Table 1_Diagnostic potential of WNT signaling gene methylation in pulmonary tuberculosis.doc by Hua Wang (13530)

“…In PTB patients, the increased SFRP1 methylation level was significantly correlated with drug-induced liver injury, pulmonary infection, and the decreased WNT3A, CTNNB1 methylation levels were respectively significantly associated with drug resistance, fever. …”

NHR-49/80 mediated FEDUS via the peroxisomal activation. by Meiyu Ruan (19929335)

“…Lower population density significantly decreased palmitic acid-induced AWC maturation. …”

Table 6_Analysis of global, regional, and national burdens of neonatal encephalopathy from 1990 to 2021: insights from the Global Burden of Disease Study 2021.doc by Shujun Tan (20011518)

“…Similarly, the global ASMR declined from 13.81 in 1990 to 9.75 in 2021, with deaths decreasing from 883,082.06 to 603,605.62, representing a 31.65% reduction. …”

Table 1_Analysis of global, regional, and national burdens of neonatal encephalopathy from 1990 to 2021: insights from the Global Burden of Disease Study 2021.doc by Shujun Tan (20011518)

“…Similarly, the global ASMR declined from 13.81 in 1990 to 9.75 in 2021, with deaths decreasing from 883,082.06 to 603,605.62, representing a 31.65% reduction. …”

Table 2_Analysis of global, regional, and national burdens of neonatal encephalopathy from 1990 to 2021: insights from the Global Burden of Disease Study 2021.doc by Shujun Tan (20011518)

“…Similarly, the global ASMR declined from 13.81 in 1990 to 9.75 in 2021, with deaths decreasing from 883,082.06 to 603,605.62, representing a 31.65% reduction. …”

Table 8_Analysis of global, regional, and national burdens of neonatal encephalopathy from 1990 to 2021: insights from the Global Burden of Disease Study 2021.doc by Shujun Tan (20011518)

“…Similarly, the global ASMR declined from 13.81 in 1990 to 9.75 in 2021, with deaths decreasing from 883,082.06 to 603,605.62, representing a 31.65% reduction. …”

Table 5_Analysis of global, regional, and national burdens of neonatal encephalopathy from 1990 to 2021: insights from the Global Burden of Disease Study 2021.doc by Shujun Tan (20011518)

“…Similarly, the global ASMR declined from 13.81 in 1990 to 9.75 in 2021, with deaths decreasing from 883,082.06 to 603,605.62, representing a 31.65% reduction. …”

Table 7_Analysis of global, regional, and national burdens of neonatal encephalopathy from 1990 to 2021: insights from the Global Burden of Disease Study 2021.doc by Shujun Tan (20011518)

“…Similarly, the global ASMR declined from 13.81 in 1990 to 9.75 in 2021, with deaths decreasing from 883,082.06 to 603,605.62, representing a 31.65% reduction. …”

Table 4_Analysis of global, regional, and national burdens of neonatal encephalopathy from 1990 to 2021: insights from the Global Burden of Disease Study 2021.doc by Shujun Tan (20011518)

“…Similarly, the global ASMR declined from 13.81 in 1990 to 9.75 in 2021, with deaths decreasing from 883,082.06 to 603,605.62, representing a 31.65% reduction. …”

Table 3_Analysis of global, regional, and national burdens of neonatal encephalopathy from 1990 to 2021: insights from the Global Burden of Disease Study 2021.doc by Shujun Tan (20011518)

“…Similarly, the global ASMR declined from 13.81 in 1990 to 9.75 in 2021, with deaths decreasing from 883,082.06 to 603,605.62, representing a 31.65% reduction. …”

Image 3_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

“…</p>Results<p>Of these, 17 patients received tocilizumab, resulting in a significant reduction in the duration of grade 3 CRS compared to those who did not receive the drug. …”

Table 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.docx by Qianyi Zhou (6196383)

“…</p>Results<p>Of these, 17 patients received tocilizumab, resulting in a significant reduction in the duration of grade 3 CRS compared to those who did not receive the drug. …”

Image 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

“…</p>Results<p>Of these, 17 patients received tocilizumab, resulting in a significant reduction in the duration of grade 3 CRS compared to those who did not receive the drug. …”

Table 2_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.doc by Qianyi Zhou (6196383)

“…</p>Results<p>Of these, 17 patients received tocilizumab, resulting in a significant reduction in the duration of grade 3 CRS compared to those who did not receive the drug. …”

Image 1_Efficacy and safety of tocilizumab in managing cytokine release syndrome after CD19 CAR-T therapy for relapsed or refractory B-cell acute lymphoblastic leukemia.tiff by Qianyi Zhou (6196383)

“…</p>Results<p>Of these, 17 patients received tocilizumab, resulting in a significant reduction in the duration of grade 3 CRS compared to those who did not receive the drug. …”

Data from The impact of human disturbances on the regeneration layer of tropical rainforests by Ricard Arasa-Gisbert (20308659)

“…The Hedges’ g index estimates the standardized mean difference and variance between a control and treatment sites and can be used in studies with a small sample size (Gurevitch & Hedges, 1999). …”

Data Sheet 1_Role of RGS17 in cisplatin-induced cochlear inflammation and ototoxicity via caspase-3 activation.zip by Raheem F. H. Al Aameri (14951800)

“…C57BL/6J mice treated with two cycles of cisplatin (3.5 mg/kg) showed a significant elevation in ABR thresholds, along with loss of outer hair cells and inner hair cells synapse. …”

Flexible Microfluidic Devices for Tunable Formation of Double Emulsion by Uditha Roshan (20841937)

“…We demonstrated that stretching increases the core size and shell thickness and decreases the generation frequency. …”